Zymeworks Inc logo

ZYME - Zymeworks Inc Share Price

$41.92 -2.2  -4.9%

Last Trade - 9:10pm

Sector
Healthcare
Size
Mid Cap
Market Cap £1.30bn
Enterprise Value £1.05bn
Revenue £43.6m
Position in Universe 1990th / 6405
Bullish
Bearish
Unlock ZYME Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZYME Revenue Unlock ZYME Revenue

Net Income

ZYME Net Income Unlock ZYME Revenue

Normalised EPS

ZYME Normalised EPS Unlock ZYME Revenue

PE Ratio Range

ZYME PE Ratio Range Unlock ZYME Revenue

Dividend Yield Range

ZYME Dividend Yield Range Unlock ZYME Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZYME EPS Forecasts Unlock ZYME Revenue
Profile Summary

Zymeworks Inc is a Canada-based biopharmaceutical company. The Company specializes in the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The Company operates through a number of platforms, including Azymetric platform, which is developed for the development of IgG-like, novel bispecific antibodies for the targeting of synergistic drug targets; Albucore platform, which is developed as a flexible and alternative platform to antibodies where it is advantageous for multi-valent therapeutic to target multiple disease targets; Effect, which comprises a library of Fc modifications that can selectively modulate the activity of recruited immune cells, and the ZymeLink Conjugation platform, which is a suite of novel protein site-specific conjugation technologies and customizable cleavable and non-cleavable linkers that is compatible with a variety of small molecule therapeutics.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated May 2, 2017
Public Since April 28, 2017
No. of Shareholders: 44
No. of Employees: 226
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange New York Stock Exchange
Shares in Issue 39,387,339
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZYME Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ZYME
Upcoming Events for ZYME
Similar to ZYME
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.